Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Scientists Aim to Reduce Animals Killed in Drug Testing

By Hiroshima University | February 1, 2017

That’s the hope of Associate Professor Noriyuki Yanaka and researchers at Hiroshima University who have developed a non-invasive way to assess the anti-inflammatory properties of fortified health foods and medications.The team from HU’s Graduate School of Biosphere Science believe their technique for examining fatty tissues will greatly reduce the numbers of lab mice sacrificed and could revolutionize medicinal drug testing.

With obesity levels soaring globally, so too are associated metabolic disorders including type-2-diabetes, cardiovascular disease, and cancers. Over-nutrition strains the body and can physically damage the bodies naturally occurring fatty tissue. The body responds to this with an influx of macrophage white-blood cells  disease-fighting cells that physically engulf pathogens.

Mouse exhibiting presence of inflamed fatty tissue using bioluminance imaging. (Credit: Hiroshima University)

While in the healthy body this should prove a positive action, previous animal studies show that macrophages can cause serious problems in obese fatty tissues. Macrophages damage already strained fat cells further, leading to inflammation and the risk of life-threatening diseases developing.It is this phenomenon that the team at Hiroshima University are interested in observing — however, their concern is not just for humans leading sedentary modern lives.

Until now, analysis of inflammation in fatty tissue required large numbers of lab mice to be terminated regularly.  

Not only does this regular termination restrict long-term observation, it also leads to many mice dying in vain, as unsatisfactory observations require fresh batches of mice to be prepared.

Professor Yanaka, conscious of the high numbers of lab mice euthanized in these studies has proposed a method that reduces not only the numbers of rodents sacrificed but also makes for more-satisfactory observations — a solution that works better for all concerned.

Associate Professor Noriyuki Yanaka. (Credit: Hiroshima University

By investigating a spectrum of lab mouse genes, and their activation in different murine tissues, the researchers at HU have been able to isolate one that is highly expressed in obese fatty tissues where macrophages are causing inflammation havoc.

That gene, Serum Amyloid A3 (Saa3), “turns-on” and can be detected when fatty tissue becomes inflamed, enabling a non-invasive drug testing method to be developed.  

To achieve this Professor Yanaka’s team attached the light-emitting luciferase gene, sourced from fireflies, to Saa3’s promoter region — creating a chimeric gene that emits light in fatty tissue suffering inflammation.

By injecting this chimeric gene into fertilized mouse eggs the team created a batch of transgenic mice — some of which were fed a natural-wild diet, and others a high-fat diet. Examination of them, while alive, using bioluminescence imaging showed the obese mice exhibiting high concentrations of light-emittance in areas where inflamed fatty tissue was found to be present — the natural-wild-diet fed mice exhibited no light emittance, thus a non-invasive method  for detecting inflammation in fatty tissue was born.

Yanaka stresses this method does not negate the need for terminating lab mice entirely as some require termination for further analysis. However, the process is much more selective and termination only occurs when it is most useful to the researchers. He says the numbers of lab mice required will drop dramatically and this could have far-reaching ramifications:

“Animal experimentation is a serious social problem in developed countries, with many animals being sacrificed in order to develop medicines, cosmetics and functional foods for humans,” Yanaka said. “What we are proposing is a way to reduce not only the number of animals which are used in experiments, but also animal experiments themselves.”

(Source: AlphaGalileo)


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50